Trial Profile
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Japanese and Chinese Adults With Uncontrolled Partial-Onset Seizures With or Without Secondary Generalization
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Jun 2021
Price :
$35
*
At a glance
- Drugs Lacosamide (Primary) ; Antiepileptic drugs
- Indications Partial epilepsies
- Focus Registrational; Therapeutic Use
- Sponsors UCB Pharma SA
- 20 May 2021 Results assessing cost-effectiveness and budget impact of perampanel versus lacosamide by using data from two studies including this study presented at the 26th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
- 04 Jul 2016 According to an Daiichi Sankyo media release, the Japanese Ministry of Health, Labor and Welfare (MHLW) has granted approval for Lacosamide (VIMPAT) as an adjunctive therapy in the treatment of partial onset seizures with or without secondary generalization in adult patients with epilepsy who have not obtained sufficient response to other antiepileptic drugs.
- 21 Dec 2015 Results of this trial were presented at the 2015 Annual Meeting of the American Epilepsy Society, according to a Daiichi Sankyo media release.